BBV152

BIOLOGICAL4 trials

Sponsors

Bharat Biotech International Limited, Masaryk University, Ocugen

Conditions

Adverse Reaction to VaccineCOVID-19COVID19 VaccineCovid19SARS-CoV Infection

Phase 2

Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults

Start: 2022-02-20End: 2023-10-31Target: 400Updated: 2023-03-27

Phase 3

An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers

Bharat Biotech International LimitedCovid19, SARS-CoV Infection

Start: 2020-11-16End: 2022-12-31Updated: 2021-03-19

Unknown Phase

COVID-19 Vaccines Safety Tracking (CoVaST)

RecruitingNCT04834869

Masaryk UniversityAdverse Reaction to Vaccine, COVID19 Vaccine

Start: 2021-04-01End: 2026-12-31Target: 30000Updated: 2022-04-06

Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older

Updated: 2022-09-22

Related Papers

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.

2021-11-11269 citations

COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines’ Side Effects

International Journal of Environmental Research and Public Health2021-07-2568 citations

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.

2021-03-08241 citations

International COVID-19 Vaccines Safety Tracking Study (CoVaST-RU): Participation of the Russian Federation

Russian Journal of Preventive Medicine2021-01-011 citations